Literature DB >> 2912165

Glomerular responses to platelet-activating factor in the rat: role of thromboxane A2.

K F Badr1, D K DeBoer, K Takahashi, R C Harris, A Fogo, H R Jacobson.   

Abstract

In view of its role as a pro-inflammatory mediator in glomerular injury, we investigated the renal cortical microcirculatory responses to the intrarenal arterial administration of platelet-activating factor (PAF) in the anesthetized euvolemic Munich-Wistar rat. Close arterial administration of PAF led to dose-dependent reductions in renal plasma flow rate (RPF), glomerular filtration rate (GFR), and filtration fraction (FF), in the absence of hypotension or hemoconcentration. Single-nephron (SN) plasma flow rate (QA), SNGFR and SNFF also fell [126 +/- 7 to 101 +/- 6 nl/min (P less than 0.005), 40.6 +/- 2.1 to 21.5 +/- 2.5 nl/min (P less than 0.005), and 0.33 +/- 0.03 to 0.21 +/- 0.03 (P less than 0.025)]. PAF increased pre- and postglomerular arteriolar resistances [2.32 +/- 0.14 to 2.73 +/- 0.19 (P less than 0.005) and 1.32 +/- 0.13 to 1.45 +/- 0.10(10)dyn.s.cm-5 (P less than 0.05)]. PAF infusion also led to a dramatic reduction in the mean value for the glomerular capillary ultrafiltration coefficient, Kf [0.058 +/- 0.012 to 0.020 +/- 0.003 nl.s-1.mmHg (P less than 0.025)]. PAF-induced changes in renal hemodynamics were abolished in the presence of the cyclooxygenase inhibitors, indomethacin and ibuprofen. When administered concomitantly with a thromboxane A2 (TxA2) receptor antagonist, PAF led to significant increases in RPF and GFR. In isolated glomeruli, PAF stimulated the biosynthesis of TxB2 in a dose-dependent manner. Thus PAF depresses rat glomerular function by inducing contraction of arteriolar and mesangial smooth muscle. These effects are likely mediated via the secondary release of TxA2.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912165     DOI: 10.1152/ajprenal.1989.256.1.F35

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Vasodilator and constrictor actions of platelet-activating factor in the isolated microperfused afferent arteriole of the rabbit kidney. Role of endothelium-derived relaxing factor/nitric oxide and cyclooxygenase products.

Authors:  L A Juncos; Y L Ren; S Arima; S Ito
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 2.  Amphotericin B nephrotoxicity.

Authors:  R Sabra; R A Branch
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

3.  Predominant functional roles for thromboxane A2 and prostaglandin E2 during late nephrotoxic serum glomerulonephritis in the rat.

Authors:  K Takahashi; G F Schreiner; K Yamashita; B W Christman; I Blair; K F Badr
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

4.  Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors.

Authors:  K Takahashi; T M Nammour; M Fukunaga; J Ebert; J D Morrow; L J Roberts; R L Hoover; K F Badr
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

5.  Leukotriene D4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis.

Authors:  T Katoh; E A Lianos; M Fukunaga; K Takahashi; K F Badr
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 6.  The role of platelet-activating factor (PAF) in experimental glomerular injury.

Authors:  A Ortiz; M Gomez-Chiarri; J L Lerma; E Gonzalez; J Egido
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  The effects of R-75,317 on antiglomerular basement membrane glomerulonephritis in rats.

Authors:  M Miyamoto; H Koike; T Sada; Y Ijima; J Fukushige; N Nakamura
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

8.  Phospholipid derived mediators and glomerulonephritis.

Authors:  E N Wardle
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

Review 9.  Annonaceae: Breaking the Wall of Inflammation.

Authors:  Ali Attiq; Juriyati Jalil; Khairana Husain
Journal:  Front Pharmacol       Date:  2017-10-20       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.